Chronic Myelomonocytic Leukaemia (CMML)

Health-Related Quality of Life, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Presenter(s)
Namrata Chandhok, MD
Thomas LeBlanc, MD, MA
Fabio Efficace, PhD
Alison R. Kavanaugh
Pamela C. Egan, MD
Wil L. Santivasi, MD
The session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium, Co-Chairs Namrata Chandhok, MD, and Thomas LeBlanc, MD, MA Topics and speakers included: How can we measure quality of life in MDS, to inform interventions? - Fabio Efficace, PhD…

Non-Transplant Therapies for Marrow Failure, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Presenter(s)
Carlos DeCastro, MD
Phil Scheinberg, MD
Regis Peffault de Latour, MD, PhD
Julian Sevilla, MD, PhD
Kasiani Myers, MD
Suneet Agarwal, MD, PhD
This session was presented at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium; Co-Chairs Carlos DeCastro, MD, and Phil Scheinberg, MD, PhD. Session topics included: -Androgens, alemtuzumab, anti-cytokine therapies (anti-IL2R, anti-IFN gamma), daratumumab…

Isolated KRAS and NRAS mutations in adults with monocytosis and/or cytopenia(s)

Original Publication Date
Article Source
External Web Content

Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…

Inhibiting ferroptosis enhances ex vivo expansion of human haematopoietic stem cells

Original Publication Date
Article Source
External Web Content

Abstract Improved ex vivo expansion of human haematopoietic stem cells (HSCs) would considerably advance transplantation and genome-engineered therapies, yet existing culture methods still allow substantial HSC loss. Here we show that this attrition is driven largely by…

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

Original Publication Date
Article Source
External Web Content

Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…

Understanding Clinical Trials

Fact Sheet - Understanding Clinical Trials

This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part

Financial Resources

Fact Sheet - Financial Resources

A list of organizations & programs that may provide financial resources & other assistance

Subscribe to Chronic Myelomonocytic Leukaemia (CMML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.